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a b s t r a c t
Chronic low dose inorganic arsenic exposure causes cells to take on an epithelial-to-mesenchymal phenotype,
which is a crucial process in carcinogenesis. Inorganic arsenic is not a mutagen and thus epigenetic alterations
have been implicated in this process. Indeed, during the epithelial-to-mesenchymal transition, morphologic
changes to cells correlate with changes in chromatin structure and gene expression, ultimately driving this
process. However, studies on the effects of inorganic arsenic exposure/withdrawal on the epithelial-to-mesenchymal transition and the impact of epigenetic alterations in this process are limited. In this study we used
high-resolution microarray analysis to measure the changes in DNA methylation in cells undergoing inorganic
arsenic-induced epithelial-to-mesenchymal transition, and on the reversal of this process, after removal of the
inorganic arsenic exposure. We found that cells exposed to chronic, low-dose inorganic arsenic exposure showed
30,530 sites were differentially methylated, and with inorganic arsenic withdrawal several differential methylated sites were reversed, albeit not completely. Furthermore, these changes in DNA methylation mainly correlated
with changes in gene expression at most sites tested but not at all. This study suggests that DNA methylation
changes on gene expression are not clear-cut and provide a platform to begin to uncover the relationship
between DNA methylation and gene expression, speciﬁcally within the context of inorganic arsenic treatment.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Environmental inorganic arsenic (iAs) exposure through contaminated water consumption represents a major public health concern
(IARC, 2004; Tapio and Grosche, 2006; Salnikow and Zhitkovich, 2008;
States et al., 2009; Cheng et al., 2012) and has been linked to cardiovascular diseases (States et al., 2009; Garcia-Esquinas et al., 2013), diabetes
(Drobná et al., 2013), and a variety of cancers including lung
(Hopenhayn-Rich et al., 1998), colorectal (Johnson et al., 2011), kidney
(Hopenhayn-Rich et al., 1998), liver (Hopenhayn-Rich et al., 1998; Chen
et al., 2004) and skin cancers (Tseng et al., 1968; Rossman et al., 2001).
Inorganic arsenic is not a direct mutagen, rather it acts through other

Abbreviations: NT, nontreated HeLa cells; iAsT, 0.5 μM sodium arsenite treated HeLa
cells; iAs-rev, reverse treated cells; EMT, epithelial-to-mesenchymal transition; DMR,
Differentially Methylated Region; iAs, inorganic arsenic; DNMTs, DNA
methyltransferases; SAM, S-adenosyl methionine; CGI, CpG island; AS3MT, arsenic
methyltransferase; qRT-PCR, quantitative real time polymerase chain reaction; 5mC, 5methylcytosine; 5′UTR, 5′ untranslated region; 3′UTR, 3′ untranslated region; TSS,
transcription start site; GO, gene ontology; GSEA, Gene Set Enrichment Analysis;
H3K4me3, Histone 3 lysine 4 trimethylation; H3K27me3, Histone 3 lysine 27
trimethylation.
⁎ Corresponding author at: 741 S. Limestone, BBSRB 273, Lexington, KY 40536, USA.
E-mail address: y.fondufe-mittendorf@uky.edu (Y.N. Fondufe-Mittendorf).

mechanisms to induce cellular transformation and epithelial-to-mesenchymal transition (EMT) (Rossman, 2003; Klein et al., 2007). Several
mechanisms have been proposed to describe how iAs-induced toxicity
promotes carcinogenesis; these include the induction of oxidative stress
(Huang et al., 1999; Harris and Shi, 2003; Huang et al., 2004), inhibition
of DNA repair, and chromosomal aberrations (Collins et al., 1995; Klein
et al., 2007). In addition to these mechanisms, recent ﬁndings indicate
that epigenetic factors, such as DNA methylation, play a central role in
aberrant gene expression resulting from iAs exposure (Li et al., 2002;
Li et al., 2008; Zhou et al., 2008, 2011).
DNA methylation, the most stable epigenetic mark, is a key factor in
regulating gene expression (Robertson, 2005; Suzuki and Bird, 2008).
This mark is catalyzed by DNA methyltransferases (DNMTs); DNMT1
is responsible for the maintenance methylation while DNMT3a and
DNMT3b perform de novo methylation (Bestor, 2000; Goll and Bestor,
2005). DNA methyltransferases facilitate this modiﬁcation by the transfer of a methyl group from S-adenosyl methionine (SAM) to the 5′ carbon of cytosine residues (Bestor, 2000). This modiﬁcation normally
occurs in regions/contexts of high CpG density, known as CpG islands
(CGIs). However, DNA methylation can also occur in non-CGI contexts.
CGIs are typically concentrated at promoter regions but can be found
in other regions (Bird, 2002) and methylation controls gene expression
differently depending on its location. The presence of 5-methylcytosine

http://dx.doi.org/10.1016/j.taap.2017.03.017
0041-008X/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

M. Eckstein et al. / Toxicology and Applied Pharmacology 331 (2017) 6–17

at promoters is usually associated with transcriptional repression (Bird,
2002). Conversely, absence of this mark, along with the presence of the
appropriate transcription factors, promotes gene expression. However,
within gene bodies and at intergenic regions, the effects of methylation
are less deﬁnitive; therefore, studies are in process to elucidate the dynamic effects of DNA methylation in those contexts. Since methylation
affects transcription factor binding ability (Perini et al., 2005), it is possible that DNA methylation functions prominently in cell and tissue
identity and functionality.
Several mechanisms have been proposed to describe how iAs affects
the DNA methylation proﬁle in cells. The ﬁrst involves the metabolism
of inorganic arsenic. During iAs metabolism, arsenic methyltransferase
(AS3MT) transfers a methyl group to arsenite, using SAM as a donor
(Miao et al., 2015); this process could lead to a depletion of SAM, which
is needed for a variety of other cellular processes. A second mechanism
involves changes in the expression of DNMTs in response to chronic exposure to iAs. In trying to understand why DNMTs would be targeted,
we found that the transcriptional repressor CTCF is targeted by iAs treatment, causing changes in CTCF occupancy at DNMT promoters (Cui et al.,
2006; Li et al., 2015a; Rea et al., 2017). Such disruption in the DNMT
expression would effect changes in DNA methylation patterns.
Several studies that focus on proﬁling of the global changes in DNA
methylation levels have been carried out in cells exposed to iAs; however, these studies have used low-resolution genome proﬁling techniques
to investigate methylation patterns (Koestler et al., 2013). Clearly
missing is an analysis of DNA methylation patterns at gene regulatory
regions such as CpG islands, promoters, and enhancers. Recently, we
carried out the ﬁrst comprehensive study of DNA methylation changes
with single-nucleotide resolution for cells chronically exposed to low
doses of arsenic (Rea et al., 2017). In the present study, we extend our
ﬁndings to determine changes in iAs-induced DNA methylation
patterns in cells with chronic low-dose iAs exposure, as well as in cells
that undergo a reversal of this treatment. Our studies include the analysis of DNA methylation proﬁles and correlations of gene expression
changes in the cells, combining unbiased whole-genome and candidate
gene approaches.
In this study, we aim to determine the effect of iAs on both permanent and reversible changes in DNA methylation and gene expression
that drive EMT. Our lab previously showed that removal of iAs resulted
in a reversal of some gene expression patterns (Riedmann et al., 2015;
Rea et al., 2016). We reasoned that since epigenetic marks are reversible, some methylation patterns would revert to the nontreated condition when iAs is removed, thereby reversing some gene expression
patterns, while others would remain stable. We therefore investigated
the adaptive changes after reversal of the exposure.
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(Diagenode Bioruptor 300) and centrifuged at 13000 rpm at 4 °C for
15 min to pellet cell debris. Protein concentration was measured using
a BCA kit (Thermo Fisher) and 30 μg of total protein were run on a
10% or 15% SDS-PAGE gel at 120 V until loading dye reached the bottom
of the gel. Proteins were transferred to polyvinylidene ﬂuoride membranes (PVDF) at 65 V for 90 min on ice. 5% milk + phosphate buffered
saline with Tween (PBST) was used to block non-speciﬁc binding to the
membranes. Membranes were incubated with primary antibodies (Cell
Signaling Technologies, Danvers, MA #9782, EMT Antibody Sampler
Kit) (in 0.5% milk + PBST) overnight at 4 °C and then with secondary
antibody (α-rabbit or α-mouse) the next day. Proteins were visualized
with ECF (GE-Typhoon FLA9500) as outlined by the manufacturer.
2.3. Quantiﬁcation of the 5-methylcytosine level in DNA
Genomic DNA was isolated from the cells and total 5-methylcytosine
(5-mC) was determined using the 5-mC DNA ELISA kit (Zymo Research
Corp., Irvine, CA, USA) per the manufacturer's instruction. Brieﬂy, DNA is
denatured and then treated with an anti-5-methylcytosine monoclonal
antibody that is both sensitive and speciﬁc for 5-mC. A secondary antibody containing horseradish peroxidase is then used to detect 5mC.
Values are expressed as a percent 5-mC in a DNA sample calculated
through a standard curve generated with specially designed controls
that are included in the kit. Each ELISA was performed in triplicate
and students t-test (p b 0.05) determined statistical signiﬁcance.
2.4. Inﬁnium MethylationEPIC BeadChip - methylation array analysis
2.4.1. Sample preparation for the chip. Genomic DNA from nontreated,
treated, and reverse treated cells was extracted using the Qiagen
DNeasy Blood and Tissue kit; samples were initially bisulﬁte converted
using the Zymo EZ-96DNA Methylation Kit (Catalog #D5004) DeepWell Format. DNA was treated with sodium bisulﬁte causing
unmethylated cytosines to convert to uracil while keeping methylated
cytosines unchanged. Then 4 μl (equivalent to 750 ng DNA) of the bisulﬁte-converted DNA was used as input for the Illumina Inﬁnium HD
Methylation Array. During this process, the bisulﬁte converted DNA
samples were denatured, neutralized, and prepared for ampliﬁcation.
The ampliﬁed DNA was enzymatically fragmented and precipitated.
The resuspended DNA samples were then dispensed onto Illumina's
Inﬁnium MethylationEPIC BeadChip, where they underwent a series of
washing, extension, and staining procedures. The BeadChips are then
coated for protection and scanned on the Illumina HiScanSQ. Once scanning was completed, the data were uploaded into GenomeStudio for
preliminary and quality control analysis.

2. Materials and methods
2.1. HeLa cell growth conditions and treatment
HeLa cells were grown using Dulbecco's modiﬁed Eagle medium
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine
serum (Sigma-Aldrich), 1% MEM nonessential amino acids (Sigma-Aldrich), and 1% penicillin-streptomycin (Sigma-Aldrich). Cells were
grown in a humidiﬁed chamber at 37 °C and 5% CO2 until they reached
80% conﬂuency. For iAs exposure, cells were treated with 0.5 μM sodium
arsenite (Sigma-Aldrich) for approximately 45 days. Time matched controls were treated with water (nontreated or NT cells). Reverse treated
cells were treated with 0.5 μM sodium arsenite until day 36, at which
point they were treated with water instead of sodium arsenite. Reverse
treated cells were harvested 10 days after treatment reversal (day 46).
2.2. Western blot analysis
Whole cell protein was extracted from 5 × 106 HeLa cells. Cells were
intermittently sonicated with 12 cycles of 30 s bursts/30 s rest

2.4.2. Data analyses.
Target success rates were determined and the
detection p-value was calculated as 1-p from the background model
characterizing the chance that the target sequence was distinguishable
from the negative control. Poor performing targets were deﬁned as having p N 0.05 and were discarded. Sample replicates were checked for an
r2 value N 0.99. For statistical analysis, beta values were calculated. The
methylation levels of CpGs were described as beta values (0 to 1)
representing the calculated level of methylation (0% to 100%). We had
two technical and two biological replicates processed by chip technique.
The Pearson correlation coefﬁcients (PCCs) were N0.99 for all the
replicates, conﬁrming a good level of reproducibility for the chip process
and indicating that the observed differential methylation between
the cells (treatments) represented true biological differences.
Functional normalization was performed using home scripts ‘Minﬁ
preprocessFunNorm’ which does the background normalization. Additionally, the dye correction was performed using noob. All CpG sites
with a detection value N 0.05, CpG sites with SNPs, as well as probes predicted to hybridize to more than one genomic location (identiﬁed by
McCartney et al. in Genomics Data, 2016) were removed. Experiments
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were done in duplicate and a high concordance was observed within
each group.
2.5. qRT-PCR
RNA was isolated from 5 × 106 HeLa cells using an RNeasy Mini Kit
(Qiagen). A reverse transcriptase reaction was set up containing iScript
Reverse Transcriptase (Bio-Rad #1708891) and 1 μg of RNA, producing
cDNA. Each qRT-PCR reaction contained 25 ng of cDNA and followed the
following reaction protocol: 1) 94 °C for 5 min; 2) 94 °C for 30 s; 3) 53–
65 °C (dependent on primer pair; Supplemental Table 1) for 30 s; 4)
72 °C for 45 s; 5) repeat 2–4 for 40 cycles; 6) 72 °C for 10 min. Primers
for the housekeeping gene, GAPDH, were made using PrimerBank. qRTPCR data was analyzed by the 2−ddCt method and student t-tests were
performed to determine statistical signiﬁcance.
3. Results
3.1. Cellular transformation and EMT
To determine the effect of iAs on the epithelial-to-mesenchymal
transition (EMT), we used the common cervical cancer cell line, HeLa,
which has been used extensively to study cell signaling and EMT
(Deng et al., 2015; Li et al., 2015b; Riedmann et al., 2015). Interestingly,
though carcinogenic, HeLa cells can still undergo EMT (Xiao et al., 2013),
and speciﬁcally, iAs-induced EMT (Riedmann et al., 2015; Rea et al.,
2016). In our experimental design (Fig. 1A), HeLa media was
replenished with 0.5 μM sodium arsenite every three to four days for

45 days to allow cells to undergo iAs-mediated EMT (iAsT). This lowdose treatment simulates chronically exposed, environmentally
relevant iAs levels that many people in mining regions experience
(Nordstrom, 2002; IARC, 2004; NTP, 2014). We conﬁrm our previous results showing that chronic low-dose treatment of cells with iAs resulted
in epithelial-to-mesenchymal transition in HeLa cells (Riedmann et al.,
2015; Rea et al., 2016; Rea et al., 2017). In addition, after continuous exposure, iAs was removed from some cultures and those cells were
grown in media without iAs for 10 more days. We called this period of
treatment without iAs “inorganic arsenic exposure reversal” (iAs-rev)
and its purpose is to simulate situations where people are removed
from chronic iAs exposure (Fig. 1A).
In previous studies, we observed EMT through cell morphology as
well as through qRT-PCR and western blot analyses of EMT markers
(Riedmann et al., 2015; Rea et al., 2016, 2017). Morphologically, we observed that NT cells maintained an epithelial phenotype in which cells
were round and small. Upon iAs treatment, cells developed a more mesenchymal phenotype, being elongated and spindle-shaped, suggestive
of EMT (Riedmann et al., 2015; Rea et al., 2016). Through qRT-PCR
and western blot analyses, we observed changes to cellular markers
characteristic of cells undergoing the EMT process. Cell adhesion
markers, such as β-catenin, Claudin-1, Claudin-3, and ZO-1, are expected to decrease in expression while transcription factors that promote a
mesenchymal phenotype, such as Snail, Slug, and Vimentin, are expected to increase in expression (Riedmann et al., 2015; Rea et al., 2016).
Additionally, upon reversal of treatment, we found that some EMT
markers exhibited a moderate reversal in expression and protein levels
(β-catenin, Slug, and Snail) while others did not revert (Claudin-3 and
Vimentin) (Rea et al., 2016). To validate that EMT is occurring in our

Fig. 1. Chronic low-dose exposure to iAs and subsequent reversal causes cells to undergo EMT. (A). Diagram of experimental design. HeLa cells were treated with 0.5 μM sodium arsenite
(iAsT) while some were mock treated with dIH2O (NT). After 36 days of iAs treatment, sodium arsenite was removed from growth media for some treated cells and replaced with dIH2O
(iAs-rev); (B). western blot analysis of EMT markers show HeLa cells undergoing iAs-induced EMT. Claudin-1 decreased with treatment, and remained decreased in the iAs-rev condition.
Some markers, like Snail, increased in the iAsT, but did not return towards NT levels in iAs-rev cells while N-cadherin and Slug increased in iAsT and returned towards NT levels.
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current studies, we analyzed protein expression changes for EMT
markers using western blot analysis and the changes in protein levels
indicate that the cells indeed had undergone EMT (Fig. 1B). We found
that Claudin-1 decreased in protein levels upon treatment and that
Slug, N-cadherin, and Snail increased upon treatment. After reversal of
treatment, some markers exhibited a moderate reversal such as Slug
and N-cadherin, indicating that there was some reversal of the EMT conditions albeit not completely. Conversely, Claudin-1 and Snail did not
revert back towards nontreated levels, which we also saw in previous
studies (Fig. 1B). These results corroborate our previous data, indicating
that cells treated with low doses of inorganic arsenic undergo EMT and
that this transition is partially reversed when inorganic arsenic is
removed.
3.2. Global DNA methylation level
After demonstrating that HeLa cells undergo EMT in response to iAs
treatment and partial reversal with iAs withdrawal, we next identiﬁed
the DNA methylation changes present in iAsT and iAs-rev cells. We
ﬁrst determined the levels of global DNA methylation in these samples
using the Zymo 5-mC DNA ELISA assay. We found signiﬁcantly higher
DNA methylation levels in iAsT cells compared to NT cells (Fig. 2). In
line with our reversal of EMT markers, we observed a reduction in global
DNA methylation levels in iAs-rev cells compared to iAsT cells, and the
amount of DNA methylation more closely resembled those in NT cells
(Fig. 2). We interpret these data as indicating that global DNA methylation is reprogrammed in these cells and may correlate with changes in
gene expression patterns.
3.3. Quantiﬁcation of DNA methylation at speciﬁc sites
Since the 5MC DNA ELISA assay is a low-resolution technique that
measures DNA methylation levels and only surveys a small sample of
CpG sites, the Inﬁnium MethylationEPIC BeadChip Array was used to
further interrogate the differential methylation patterns globally, and
at speciﬁc genes targeted in iAs-mediated EMT and reversal. This array
has 853,307 CpG (850 K) sites, providing the ability to interrogate
DNA methylation changes not only at promoters and gene bodies, but
also at unexplored regions such as enhancers. Indeed, incorporated
into this Chip are 333,265 CpG sites, including enhancer regions identiﬁed by the ENCODE (The, 2012; Siggens and Ekwall, 2014) and
FANTOM5 (Lizio et al., 2015) projects. Thus, this is a valuable tool to decipher how DNA methylation changes in unexplored territories, such as
enhancer sequences, contribute to arsenic-mediated diseases.

Fig. 2. Global DNA methylation levels are increased with 0.5 μM arsenite exposure. Results
from the 5mC-ELISA show that 0.5 μM sodium arsenite exposure signiﬁcantly increased
global DNA methylation levels in HeLa cells. iAsT cells that had exposure removed (iAsrev) showed a signiﬁcant decrease from the iAsT DNA methylation levels; however,
these are still signiﬁcantly increased from NT levels. ELISA was performed in triplicate
and error bars reﬂect the SEM of these replicates. Students t-test was performed for
signiﬁcance (p b 0.05); * denotes difference from NT † denotes difference from iAsT to
iAs-rev.
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3.4. Global methylation changes
To identify possible targets for iAs-mediated DNA methylation
reprogramming, we conducted methylation proﬁling of the NT, iAsT,
and iAs-rev cells. We ﬁltered DNA methylation data according to the
following criteria: methylation changes should be more than two-fold
and should have a p-value b 0.05 (Supplemental Figs. 1 and 2). Of the
853,307 CpG sites, signiﬁcant differences in DNA methylation were observed at 30,530 CpG sites in iAsT when compared to NT, of which 67%
(20,314 CpG) were hypermethylated and 33% (10,216 CpGs) were
hypomethylated (Fig. 3). Upon reversal of arsenic treatment, some of
the methylated sites did not revert to normal methylation in NT conditions. A total of 53% of the DMRs still differed from NT cells; 77% of these
CpGs (10,996 CpGs) were hypermethylated, while 23% (3,3339 CpGs)
were hypomethylated (Fig. 3). We then compared the DMRs in iAsT
cells and iAs-rev cells. We observed that ~40,000 sites had reverted towards the wildtype status - 20,997 hypomethylated and 20,589
hypermethylated (Fig. 3). We hypothesize that although many DMRs
revert to NT conditions, some were not reversed completely and so
were still measured as DMRs by our analysis. While these global measurements are useful, they do not show differential methylation at speciﬁc gene regulatory regions.
3.5. iAs mediated DNA methylation changes in CGIs and non-island regions
Methylation is often concentrated at CGIs but can also be found in
the regions surrounding CGIs (Fig. 4A). According to Illumina, a CGI is
deﬁned as a region in which there is GC content N 50% in at least a 200
base pair region. Comparative analysis of the methylation patterns in
CGIs, shores, shelves and open seas revealed signiﬁcant differences in
methylation patterns across NT, iAsT, and iAs-rev cells in certain CGI-related regions. The shelves (in blue), across all of the comparisons, only
exhibited 2–3% hypo- or hypermethylation changes, indicating that
DNA methylation of these speciﬁc regions may not play a prominent
role in iAs-mediated EMT (Fig. 4B–D, all pie charts). For the shores (in
purple), a slight decrease in hypomethylation was observed when comparing iAs-rev v. NT and iAsT v. NT (Fig. 4B and C, top pie charts). The
most prominent changes in hypomethylation were observed within the
CGIs (in orange) and open sea regions (in green). There was an increase
in hypomethylation (15% to 25%) at CGIs upon reversal (Fig. 4B and C, top
pie charts). On the other hand, in the open sea regions, the amount of hypomethylation was reduced upon reversal (55% to 49%) (Fig. 4B and C,
top pie charts). This shift in the ratio of CGI to open sea hypomethylation

Fig. 3. Methylation EPIC BeadChip Assay reveals global DNA methylation changes between
NT, iAsT, and iAs-rev. Comparison of loci from NT v. iAsT shows that 67% of loci on the chip
are hypermethylated in iAsT, while only 33% are hypomethylated. Comparison of
methylation loci between NT and iAs-rev shows that 77% of loci are hypermethylated in
iAs-rev while only 23% are hypomethylated. Comparison of iAsT and iAs-rev reveals that
the loci are approximately equal for hyper- and hypomethylation, suggesting that when
iAs is removed many loci return towards NT levels.
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Fig. 4. DNA methylation patterns show changes both within CGIs and outside of CGIs during iAs-mediated EMT. (A). Diagram showing the relationship of CGIs and neighboring regions. CGI
is deﬁned as N50% CG content in at least a 200 base pair region. The north shore is 0–2000 bp upstream of the CGI and north shelf is 2001–4000 bp upstream of the CGI. The south shore is
0–2000 bp downstream of the CGI and the south shelf is 2001–4000 bp downstream of the CGI. Open sea regions are N4000 bp outside of the CGI. (B). Regional methylation changes
between iAsT v. NT (C). Regional methylation changes between iAs-rev v. NT (D). Regional methylation changes between iAs-rev v. iAsT. Levels of methylation in shelves and shores
stay relatively unchanged between groups and hyper- or hypomethylation. Prominent methylation changes occur at the CGIs and out in the open seas.

could suggest that hypomethylation changes at the CGIs are more
permanent while hypomethylation changes at the open seas are more
transient and more prone to reversal when iAs treatment is removed.
In the shores (in purple), a slight increase in hypermethylation was
observed when comparing iAs-rev v. NT and iAsT v. NT, which compensates for the slight decrease in hypomethylation, noted above (Fig. 4B
and C, bottom pie charts). This shift in differential methylation at the
shores was conﬁrmed by the presence of more hypermethylation than
hypomethylation in the iAs-rev v. iAsT comparison in Fig. 4D. This ﬁnding could suggest that the changes in the hypomethylated loci are more
transient, or that the hypermethylation previously observed in treated
cells is more permanent. At the CGIs, there is an increase in hypermethylation (11% to 14%) upon arsenic withdrawal, similar to the increase
in hypomethylation in that region (Fig. 4B and C, bottom pie charts). For
iAs-rev v. iAsT, the CpG islands exhibited 12% hypomethylation and 13%
hypermethylation (Fig. 4D). In the open sea regions, the amount of
hypermethylation was reduced from 66% to 61% upon reversal (Fig. 4B
and C, bottom pie charts). Both hypo- and hypermethylation were reduced to a similar extent in the open seas after arsenic treatment was
removed. When comparing iAs-rev to iAsT, the open sea represented
64% of the hypomethylated regions and 58% of the hypermethylated regions (Fig. 4D). The decrease in hypermethylation at the open seas and
the increase in hypermethylation at CGIs after iAs withdrawal (which
was also seen with hypomethylation) could indicate that differential
methylation in the open seas is not as permanent as differential methylation in the CGIs.
3.6. iAs-mediated DNA methylation changes in genes and gene regulatory
regions
There are several regulatory regions within a gene that modulate
gene expression and repression (Fig. 5A). We asked if there were any

transient and/or permanent iAs-mediated methylation changes within
these regions. We compared the methylation proﬁles across different
regions of genes – 5′ and 3′UTRs (orange and gray respectively), gene
body (purple), ﬁrst exon (green), and regions 200 and 1500 base pairs
(bp) upstream to the transcription start sites (TSS200 blue and
TSS1500 red). When compared to NT cells, differential hypomethylation
in iAsT cells is as follows – 25% at TSS1500, 11% at TSS200, 15% at 5′UTR,
6% at ﬁrst exon, 41% within the gene bodies and 2% within the 3′UTR
(Fig. 5B, left bar). In all regions analyzed, there is a similar amount of
hypo- and hypermethylation changes, except at the gene body and
TSS1500, where we observed 41% hypomethylation to 49% hypermethylation and 25% hypomethylation to 19% hypermethylation. (Fig.
5B). We next asked if these methylation changes can be reversed by
comparing DNA methylation patterns in NT cells and iAs-rev cells.
Focusing mainly on the regions that were strongly differentially methylated, we ﬁrst observed a 30% hypomethylation and a 45% hypermethylation change within the gene body (Fig. 5C). This seems to indicate a
reversal of methylation patterns when considering the changes seen
in iAsT cells in the gene body region. Surprisingly, we also observed a
dramatic change in methylation at the ﬁrst exon – 22% hypomethylation
and 6% hypermethylation (Fig. 5C). However, our understanding of the
implication of this shift in hypomethylation towards the ﬁrst exon at the
moment is not clear. Furthermore, the TSS1500, which exhibited 25%
hypomethylation and 19% hypermethylation in iAsT cells compared to
NT cells (Fig. 5B), also exhibited differential methylation in the reverse
treated cells (Fig. 5C). In reversed conditions, compared to NT cells,
the differential methylation pattern is 18% hypomethylation and 20%
hypermethylation, which is the opposite of what was observed in iAsT
cells, indicating that reversal of methylation patterns may be occurring
upon removal of iAs treatment. In most cases, we observed some reversal in DNA methylation though it was not complete. To test directly if
this is true, we compared methylation patterns in iAsT v. iAs-rev cells.
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Fig. 5. DNA methylation patterns within gene regulatory regions reveal large changes within gene bodies, at the 1st exon, and 200–1500 bp upstream of start of transcription. (A). Diagram
mapping gene regulatory regions. TSS1500 is 200–1500 bp upstream of transcription start site (TSS), TSS200 is 1–200 bp upstream of TSS, 5′UTR is the 5′ untranslated region, 1st exon is
the ﬁrst translated region, gene body includes all other exons and all introns, and 3′UTR is the 3′ untranslated region where translation ends. Outside of the TSS1500 and 3′UTR is
considered intergenic. (B). Gene regulatory methylation differences between iAsT and NT. (C). Gene regulatory methylation differences between iAs-rev and NT. (D). Gene regulatory
methylation differences between iAs-rev and iAsT. Methylation within gene regulatory regions is generally stable throughout the treatment groups. Gene body and TSS1500
methylation shows the most variation between hyper- and hypomethylated DMRs.

Here too, we still observed differential methylation at the sites tested.
The gene body had 52% hypomethylation and 48% hypermethylation
(Fig. 5D). The TSS1500 exhibited 20% hypomethylation and 24% hypermethylation (Fig. 5D). These ﬁndings verify that reversal of iAs treatment reversed DNA methylation patterns in gene regulatory regions,
albeit not completely.
In order to better understand the DNA methylation changes occurring in genic regions, we performed Venn diagram comparisons of the
differentially methylated genes. To begin, we compared those genes
that are differentially methylated after iAs treatment (iAsT v. NT) with
those that are differentially methylated after reversal of treatment
(iAs-rev v. NT). The overlapping genes, of which there are 3582, are
genes that had more permanent changes in methylation (Supplemental
Fig. 3A); our reasoning being that these differential methylation patterns are present in both iAsT and iAs-rev cells.
Next, we identiﬁed those genes whose methylation patterns reversed after removal of iAs by comparing genes that were differentially
methylated after treatment (iAsT v. NT) to those that are differentially
methylated between iAs-rev and iAsT cells. This comparison resulted
in 6825 overlapping genes (Supplemental Fig. 3B). We consider these
genes as those with methylation patterns that had reversed to normal
conditions because the iAs methylation state is similar to NT but
different from iAsT cells. This is further conﬁrmed by looking at the
overlap of genes that were hypomethylated in the iAs-T cells and
those that were hypermethylated in the iAs-rev. Comparing these
groups showed that about 82% of hypomethylated genes in iAsT
showed hypermethylation in the iAs-rev (3472 genes of 4236 total
genes), while 71% of genes that were hypermethylated in iAsT showed
hypomethylation in iAs-rev cells (4103 genes of 5774 total genes)
(Supplemental Fig. 4).
Finally, we compared genes that were differentially methylated in
iAs-rev cells to those that were differentially methylated between iAsrev and iAsT cells. There were 4490 overlapping genes and we interpret
these genes as those that are in transition between the NT and iAsT
methylation state since their methylation state did not remain permanently changed but also did not completely revert to normal levels
(Supplemental Fig. 3C).

3.7. iAs mediated DNA methylation changes at promoter associated regions
Promoter methylation is normally associated with gene repression.
Thus to gain insight into the function of iAs-mediated reprogramming
of DNA methylation patterns, we next focused our analyses of DNA
methylation changes at promoter regions. Comparing iAsT to NT cells,
we observed a near 50% hypomethylation in promoter-associated regions, of which 3.71% hypomethylation was associated with cell type
speciﬁc promoter regions (Fig. 6A, top pie chart). This result is reasonable considering we are using the same cell type throughout this
study. We next investigated if hypomethylation changes in promoter
associated regions persisted after reversal of treatment. It seems that
in iAs-rev cells (iAs-rev v. NT), there was little change – 48.58% to
49.03%, in promoter-associated hypomethylation in iAsT cells compared
to iAs-rev cells (Fig. 6A and B, top pie charts). This may suggest that hypomethylation in promoter associated regions is stable and permanent
and does not revert back to normal conditions upon reversal of iAs
treatment.
We next analyzed hypermethylation at promoters. In iAsT cells,
there was 38% hypermethylation in promoter-associated regions with
3.24% hypermethylation associated with cell type speciﬁc promoter regions when compared to NT cells (Fig. 6A, bottom pie chart). Interestingly, after withdrawal of iAs treatment (iAs-rev v. NT), there was a
large increase in hypermethylation at promoter-associated regions
(38.16% to 60.66%) (Fig. 6A and B, bottom pie charts). This was also accompanied by a decrease in hypermethylation in unclassiﬁed regions
(25.68% to 19.8%) and unclassiﬁed cell type speciﬁc regions (30.83% to
14.78) (Fig. 6A and B, bottom pie charts). This shift in ratio could suggest
that hypermethylation in promoter-associated regions is more permanent while hypermethylation in unclassiﬁed regions is more transient
and able to revert back to normal levels after iAs withdrawal. The
stark increase in hypermethylation at promoter-associated regions is
validated by a higher ratio of hypermethylation than hypomethylation
in that region in the iAs-rev v. iAsT comparison (Fig. 6C). While investigating DNA methylation changes within speciﬁc gene regions is advantageous for understanding their function, our understanding of DNA
methylation in non-promoter regions is still in its infancy. In this
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Fig. 6. DNA methylation level changes at promoter associated regions reveal large changes within the promoter and unclassiﬁed regions. Comparison of DMRs within different promoter
types. (A). Regional promoter-associated methylation differences between iAsT and NT. (B). Regional promoter-associated methylation differences between iAs-rev and NT. (C). Regional
promoter-associated methylation differences between iAs-rev and iAsT. Promoter methylation changes are most apparent at promoter associated (dark green) and unclassiﬁed regions
(purple), which suggests that iAs targets distinct promoters and regions in methylation changes.

study, we have focused our attention to promoter and gene body methylation at speciﬁc genes and the correlation of their methylation status
to gene expression levels.
3.8. Coupling of differential methylation and differential gene expression at
speciﬁc loci
Next we asked whether these differential methylation patterns affect gene expression at the transcript level. DNA methylation present
at the promoters of genes is typically associated with gene repression,
and demethylation leads to gene expression (Bird, 2002; Perini et al.,
2005). On the other hand, the function of DNA methylation in gene
body regions is not as deﬁnitive. It seems that methylation in the gene
body functions in a manner opposite to that in the promoter region
(Jjingo et al., 2012; Yang et al., 2014). In gene bodies, hypomethylation
correlates with gene repression while hypermethylation correlates with
gene expression (Yang et al., 2014). Additionally, DNA methylation in
the gene body has been linked to regulation of alternative splicing so
the full breadth of its function is still limited (Maunakea et al., 2013;
Lev Maor et al., 2015; Yearim et al., 2015). To examine the impact of
DNA methylation changes on gene expression in our experimental conditions, RNA was extracted from NT, iAsT and iAs-rev cells. This RNA was
converted to cDNA and used for quantitative real time PCR analysis
(qRT-PCR). For this analysis, we chose genes that showed signiﬁcant differential methylation (Fig. 3) at the promoter region or within the gene
body and that could potentially be implicated in EMT.
The ﬁrst gene examined was CORO1B, which is important in cell motility regulation (Williams et al., 2012), and has hypomethylation at the
promoter region (Table 1). qRT-PCR analysis at the transcript level of
this gene showed an increase in gene expression in iAsT cells (Fig.
7A), correlating with the observed hypomethylation at the promoter region of this gene (Table 1). The level of gene expression remained high
even after iAs was removed (iAs-rev cells), indicating that this change is
more permanent. Interestingly, we were not able to identify any significant change in DNA methylation at the promoter of this gene in iAs-rev

cells, possibly due to the cutoff stringency applied in the differential
methylation analysis. The second gene we tested was PPME1, which
plays a role in malignant glioma progression (Puustinen et al., 2009).
qRT-PCR analysis showed no increase in gene expression in iAsT cells,
though our genome-wide methylation data indicated this region as
being hypermethylated (Table 1). This could possibly be explained by
the fact that not all CpGs regulate gene expression. On the other hand,
in iAs-rev cells, a signiﬁcant increase in gene expression was observed
(Fig. 7A), We also investigated the PPM1L gene, which is known to repress apoptosis (Ren et al., 2014). Expression levels of this gene were increased in both iAsT and iAs-rev cells compared to NT cells (Fig. 7A).
These gene expression changes correlated positively with the increase
in DNA methylation in the gene body of this gene in both iAsT and
iAs-rev cells compared to NT cells (Table 1).
Five genes exhibited prominent downregulation after iAs treatment
(Fig. 7B). For CDH12, expression decreased in iAsT cells and this decrease persisted with iAs-reversal (Fig. 7B). CDH12 is a type II classical
cadherin protein (Shan et al., 2004) and the changes in its expression
correlated with gene body hypomethylation, as well as promoter hypermethylation, in iAsT cells compared to NT cells (Fig. 7B and Table 1). The
decrease in expression from iAsT to iAs-rev also correlates with promoter hypermethylation identiﬁed in our genome-wide methylation studies. ARID5B, which is involved in histone demethylase complexes
(Baba et al., 2011), had a decrease in expression in iAsT cells and
remained at that level even in iAs-rev cells (Fig. 7B). This is somewhat
surprising considering ARID5B has hypomethylation in its promoter region in iAs-rev cells (Table 1). For DYNC1I2, a member of the dynein intermediate chain family (Kuta et al., 2010), a decrease in gene
expression was observed in iAsT cells compared to NT cells, while iAs removal resulted in upregulation of DYNC1I2 (Fig. 7B), correlating with
the promoter hypomethylation observed in the microarray (Table 1).
PRDX1, a peroxiredoxin family member, showed a decrease in expression during iAs treatment correlating with promoter hypermethylation
in iAsT cells (Fig. 7B and Table 1). After removal of iAs, gene expression
returned to normal levels (Fig. 7B). Lastly, gene expression at the EPC1
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Table 1
Expected methylation patterns for genes investigated for gene expression changes.

Methylation patterns identiﬁed by the Inﬁnium BeadChip Microarray for each gene that was investigated for gene expression changes by qRT-PCR; the expected gene expression patterns based on methylation are presented. Shaded cells indicate
that the expected expression was validated by our qRT-PCR results.

Fig. 7. Correlation of differential methylation and gene expression. (A). Three genes were upregulated with iAs treatment. CORO1B and PPME1 both increased in expression with iAsT and a
further increase was observed in iAs-rev. PPM1L increased in iAsT, but shifted towards NT levels with iAs-rev. (B). Seven genes were downregulated with iAs treatment. CDH12 and ARID5B
decreased expression levels with iAsT as well as with iAs-rev. DYNC12, PRDX1 and EPC1 all decreased expression levels with iAsT, but with iAs-rev the expression levels increased closer to
or even above NT levels. qRT-PCR reactions were performed in triplicate. * indicates a signiﬁcant change when iAsT or iAs-rev is compared to NT and † indicates a signiﬁcant change
between iAsT and iAs-rev with p-value b 0.05.
Error bars are from triplicate experiments and represent SEM.
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gene, a polycomb group member (Huang et al., 2014), correlated to the
observed methylation changes – decreased gene expression in iAsT cells
compared to NT cells with moderate reversal in iAs-rev cells, corresponding with gene body hypomethylation in iAs-rev compared to NT
cells. So too, an increase in gene expression in iAs-rev cells compared
to iAsT cells corresponded to the observed hypermethylation at the
gene body of the EPC1 gene for iAs-rev v. iAsT (Fig. 7B).
The fact that expression of some genes such as PPM1L, DYNC1I2,
PRDX1, and EPC1 reverted to normal levels in iAs-rev and that those
gene expression changes correlate to reversal of DNA methylation patterns suggests the role of epigenetics in this process. However, other
changes instigated by iAs treatment were more permanent, such as
the gene expression changes seen for CORO1B, PPME1, CDH12, and
ARID5B and suggest that either these epigenetic factors were not reversed or that other factors together with epigenetics are stabilizing a
more permanently changed gene expression state of the gene.
3.9. Global correlation of gene expression pattern with DNA methylation
patterns
In order to further understand the biological signiﬁcance of differential methylation in iAsT and iAs-rev cells, we examined the overlap of
genes that were both differentially methylated as well as differentially
expressed at the transcript level. For this analysis we reanalyzed our
previous dataset (GSE60760) of iAs-mediated differentially expressed
genes (Riedmann et al., 2015). To understand the pathways targeted
in iAsT, we analyzed the overlap between genes differentially expressed
in iAsT cells and those differentially methylated in iAsT cells. There were
270 genes that were both differentially methylated and differentially
expressed in cells treated with inorganic arsenic (Supplemental Fig.
5A). For the sake of simplicity, Venn diagram analysis was performed
on all genes that were differentially expressed as well as differentially
methylated.
We then performed gene ontology (GO) analyses using the Gene Set
Enrichment Analysis (GSEA) to identify regulatory pathways affected by
both differential methylation and differential expression. Our analyses
show that signal transduction pathways and development processes
are enriched, indicating that these pathways are targeted by iAs (Table
2). Since we observed that iAsT cells were undergoing EMT, we analyzed the target genes for oncogenic signatures. Our analysis showed
that some of the genes with differential methylation and differential
gene expression are involved in abnormal expression of K-RAS (an oncogene) in epithelial cells, particularly lung, breast, and kidney tissue
(Supplemental Table 2).
We next asked if these pathways are still targeted in iAs-rev cells.
We identiﬁed 187 genes that are both differentially methylated and differentially expressed in iAs-rev cells (Supplemental Fig. 5B). These
genes represent those whose methylation patterns did not revert to
normal levels and were more permanently changed. GO analysis of
these genes showed enrichment in biological processes such as

Table 2
Gene ontology of differentially methylated and differentially expressed genes (iAsT v. NT).
GO term

Number of genes

p-Value

Intracellular signal transduction
Intrinsic component of plasma membrane
Receptor binding
Cell development
Tissue development
Movement of cell or subcellular component
Regulation of cell death
Response to endogenous stimulus
Negative regulation of response to stimulus
Protein phosphorylation

36
36
32
31
32
29
30
29
28
23

3.05E−13
1.22E−12
2.93E−11
5.74E−11
5.97E−11
8.81E−11
5.52E−10
1.67E−09
1.74E−09
2.43E−09

Gene ontology terms of differentially methylated and differentially expressed genes comparing iAsT to NT (270 total genes).

Table 3
Gene ontology of differentially methylated and differentially expressed genes (iAs-rev v.
NT).
GO term

Number of genes

p-Value

Intrinsic component of plasma membrane
Cell development
Response to oxygen containing compound
Small molecule metabolic process
Response to nitrogen compound
Tissue development
Neuron part
Cell junction
Cytoskeleton
Response to endogenous stimulus

32
23
22
25
17
22
20
19
25
21

3.90E−14
7.07E−09
1.92E−08
1.96E−08
4.21E−08
9.99E−08
1.01E−07
1.11E−07
1.52E−07
2.02E−07

Gene ontology terms of differentially methylated and differentially expressed genes comparing iAs-rev to NT (187 total genes).

development and metabolic processes (Table 3). Investigating the oncogenic signature of these genes also revealed that they are involved in abnormal expression of K-RAS in lung, breast, and kidney epithelial tissue,
similarly to iAsT cells (Supplemental Table 3). This could indicate that
while some genes are reverting back to normal levels of expression,
the genes that do not revert are driving the carcinogenic potential of
iAs treatment.
Finally, we investigated those genes that are differentially methylated between iAs-rev cells and iAsT cells. These genes represent the group
of genes that are transient and return to a more normalized condition
after iAs removal (Supplemental Fig. 5C). GO analysis of these genes revealed enrichment in biological processes such as signal transduction,
metabolism, and cell death (Table 4). Their oncogenic signatures again
showed dysregulation of K-RAS in epithelial cells in lung, kidney, and
breast tissue (Supplemental Table 4). A complete gene ontology listing
of these genes with regards to their hyper- and hypomethylation state
is found in Supplemental Tables 5–7.
In summary, we show that differential methylation inﬂuences differential expression, both during treatment and after the reversal of treatment. While some differential methylation and differential expression
changes remained after reversal of treatment, others reversed back to
normal conditions. Since the breadth of the impact of methylation is
not completely known, we also observed that some methylation
patterns which were reversed did not correlate with changes in gene
expression. Additionally, it seems that even though some genes are reversed, the cells are still poised in an oncogenic state, as revealed by
the oncogenic signatures. However, our data provides a platform enabling the probing of DNA methylation patterns, reversal of those patterns, and the function either in promoting direct gene expression
and/or in the possible recruitment of factors that might aid in gene
expression. This is especially intriguing as we observed that the K-RAS
regulatory process might be speciﬁcally targeted by iAs in disease
pathogenesis.
Table 4
Gene ontology of differentially methylated and differentially expressed genes (iAs-rev v.
iAsT).
GO term

Number
of genes

p-value

Intrinsic component of plasma membrane
Receptor binding
Intracellular signal transduction
Regulation of cell death
Phosphate containing compound metabolic process
Negative regulation of cell death
Response to endogenous stimulus
Response to oxygen containing compound
Biological adhesion
Neurogenesis

46
38
39
36
42
27
35
34
29
34

5.76E−17
4.46E−13
6.68E−13
8.35E−12
1.18E−11
2.35E-11
2.39E−11
2.79E−11
4.15E−11
4.16E−11

Gene ontology terms of differentially methylated and differentially expressed genes comparing iAs-rev to iAsT (322 total genes).
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4. Discussion
To date, few studies have identiﬁed speciﬁc gene loci that are differentially methylated in response to chronic iAs exposure. The dose used
in our experiments is biologically relevant and mimics the dosage many
living in mining regions are exposed to daily (Nordstrom, 2002; IARC,
2004; NTP, 2014). Sadly, in some countries, people are exposed to
even higher amounts on a regular basis (Tsuda et al., 1995; Drobná et
al., 2013; Koestler et al., 2013). Ours is the ﬁrst study to distinguish between permanent and reversible DNA methylation changes using data
from cells with treatment reversal. The treatment group that experienced reversal of treatment is also biologically relevant as it imitates
the case in which people move away from an area that has chronic
low dose arsenic exposure, quit smoking, or otherwise remove themselves from environments where they are experiencing high levels of
inorganic arsenic. All of these situations happen frequently and while
these people experience a cessation of exposure, the biologic effects
may still persist, as shown by this study.
Our studies show that chronic low-dose exposure to iAs leads to
global methylation changes (Figs. 2 and 3) as well as differential methylation in gene regulatory regions (Figs. 4–6) and speciﬁc genes (Table
1). Differential methylation is concentrated to CGIs (Fig. 4), upstream
promoter regions, and gene bodies (Fig. 5). The differential methylation
correlates to changes in gene expression which may be a driving factor
in the epithelial-to-mesenchymal transition (Figs. 1 and 7). Upon reversal of treatment, some methylation and expression changes revert to
normal conditions and others do not (Fig. 7 and Table 1). Ontology analysis of genes targeted in iAs-mediated differential methylation patterns
revealed an enrichment of cellular processes, such as cell signaling and
development, after initial iAs exposure and enrichment of processes involved in metabolism after iAs withdrawal (Tables 2–4).
Our study is unique in its investigation of biological consequences of
removal of iAs exposure. The initial insult of chronic low dose exposure
to iAs is clearly detrimental due to its ability to cause cellular transformation and EMT (Riedmann et al., 2015; Rea et al., 2016; Rea et al.,
2017). However, the ramiﬁcations of iAs exposure do not fully disappear when exposure ends. It appears that while some changes partially
revert back to normal conditions after exposure is removed, many
changes remain in their abnormal state (Fig. 1). Previous studies
showed this partial reversal in morphology, gene expression and protein levels of EMT markers, DNA methylation patterns, and gene expression patterns (Riedmann et al., 2015; Rea et al., 2016; Rea et al., 2017).
What we are now showing is methylation and gene expression changes
due to withdrawal of iAs exposure. For DNA methylation and its effect
on gene expression, we hypothesize that the genes that remain differentially methylated and expressed, such as CORO1B and CDH12, are
driving transformation and EMT, while those that revert back to normal
levels of methylation and expression, such as DYNC1I2 and EPC1, are
involved in early adaptation to iAs exposure and are less involved in
transformation and EMT. Additional studies will be needed to identify
speciﬁc genes as drivers or passengers. By identifying speciﬁc genes
that are differentially methylated between iAsT and its withdrawal,
we can parse out which genes are still altered after reversal and which
revert to a more normal phenotype. We hypothesize that as cells undergo iAs-mediated EMT, hypomethylation may be occurring at oncogenes
while hypermethylation may be occurring at tumor suppressors.
We are also intrigued and encouraged by the fact that our previous
studies in BEAS-2B cells and our current study in HeLa cells show similar
results in EMT markers, DNA methylation patterns, and carcinogenic
potential (Riedmann et al., 2015; Rea et al., 2016, 2017). This ﬁnding
indicates that HeLa cells can be used as an effective model for chronic
low-dose iAs-mediated epithelial-to-mesenchymal transition. We
witnessed similar changes in cell morphology expression and protein
levels of EMT markers in both cell types. Additionally, we found that
DNA methylation instigates changes in gene expression patterns that
contribute to EMT for both cell types. Furthermore, HeLa cells and
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BEAS-2B cells returned similar gene ontology results for pathways and
processes that are being targeted in iAs treatment such as cell signaling
and neurogenesis (Tables 2–4) (Rea et al., 2017). As would be expected,
there were some minor differences between the results we observed in
HeLa cells compared to BEAS-2B cells. For example, BEAS-2B cells had
slight global hypomethylation while HeLa cells had slight global hypermethylation upon treatment (Rea et al., 2017). Differences could be due
to the state of the cells used in the experiments. In our earlier studies,
we used non-carcinogenic cells, whereas in this study, HeLa cells are already carcinogenic. Even though one cell line is carcinogenic and the
other is not, iAs caused EMT in both and we believe that similar mechanisms are driving EMT in both cell lines. Transformation and carcinogenesis are dynamic processes that rely on several mechanisms, EMT
being one of them. It seems that in HeLa cells, iAs treatment pushes
EMT even further. It would be interesting to compare the changes
seen in BEAS-2B and HeLa to determine which changes are contributing
to cellular transformation and which are contributing to EMT.
For the most part, our expression data matched what we would expect based on the methylation present in the gene (Fig. 7). However, a
few genes, such as PPME1, exhibited expression changes that were opposite of what we would expect due to the methylation data. One explanation is that not every CpG is able to inﬂuence gene expression with its
methylation status; some CpGs are regulatory and others are not. With
so much data, it's possible that not every CpG is regulatory. Some CpGs
could be functioning as a location for other transcription factors or proteins to bind that may have functions other than mediating gene expression (Maunakea et al., 2013; Nalabothula et al., 2015). For many
of the genes we investigated, there was differential methylation in several regions. In our data set, some genes had antagonistic methylation
changes such as hypomethylation at one CpG in the promoter and
hypermethylation at another CpG in the same promoter. It's been proposed that methylation may function differently depending on whether
it's in an intron or exon (Lev Maor et al., 2015). Further research is needed to answer these questions and to understand the full function of gene
body methylation in the context of low dose arsenic exposure. Clearly,
we are at the beginning of understanding the full function of DNA methylation. Interestingly, recent studies have linked methylation changes to
alterations in alternative splicing patterns (Maunakea et al., 2013; Lev
Maor et al., 2015; Yearim et al., 2015). Our own previous studies implicated all of the genes from our gene expression experiment as having alternative splicing changes (Supplemental Table 8).
The vastness of the data we gained from the Inﬁnium
MethylationEPIC BeadChip Array underscores the complexity of differential DNA methylation in cells, and therefore the depth of our understanding. For instance, tens of thousands of loci are differentially
methylated in response to low dose arsenic exposure and/or reversal
of treatment (Fig. 3 and Supplemental Fig. 2); which of them is actually
regulatory is the subject of additional study. However, inorganic arsenic
is known to cause detrimental effects through mechanisms other than
epigenetics, such as reactive oxygen species (Carpenter et al., 2011; Li
et al., 2014; Zhang et al., 2015). It is also possible that both mechanisms
are working together, enhancing biologic actions to drive the carcinogenic potential of iAs (He et al., 2012; Kang et al., 2012). Further studies
to understand this cooperation would be interesting. In addition to ROS,
DNA methylation is also known to interplay with other epigenetic modiﬁcations such histone variants and histone post-translational modiﬁcations (Chervona et al., 2012; Riedmann et al., 2015; Rea et al., 2016).
Because other epigenetic marks are altered in iAs-mediated EMT, it is
plausible that they all work collectively. For example, dysregulation of
histones H2B and H3 has been implicated in iAs-mediated transformation and EMT (Brocato et al., 2015; Rea et al., 2016). Additionally, alterations in histone post-translational modiﬁcations have been shown in
iAs-treated conditions including upregulation of the repressive mark
H3K27me3 and activation of the mark H3K4me3. It is hypothesized
that crosstalk between all of these epigenetic marks – DNA methylation,
histone variants, and histone post-translational modiﬁcations – control
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the chromatin landscape present in iAs treated cells. For example, DNA
methylation and H3K27me3 are known to be coregulated and both dynamically monitor DNA accessibility and gene expression (Hagarman et
al., 2013; de la Calle Mustienes et al., 2015). Therefore, the full implications of iAs exposure cannot fully be appreciated without understanding
the crosstalk between epigenetic marks.
In conclusion, this study presents genome-wide changes to DNA
methylation levels, as well as changes in gene expression in HeLa cells
that were exposed to iAs at chronic low-dose levels, and also in cells
that had the arsenic removed. We found that in many cases, the changes
seen in cells exposed to iAs returned to near NT levels; these regions
may be important in the cellular response to the iAs. However, many
genes either do not revert to NT levels, or show an increased change
in DNA methylation and gene expression. These genes may be involved
in the EMT process that drives the carcinogenic effects with chronic
low-dose iAs exposure. Our results provide a platform to develop potential epigenetic therapeutics in iAs-mediated carcinogenesis. Such
studies could be extended to other environmental toxicants to enhance
the understanding of their impact on the epigenome and gene
expression.
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